InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
InflaRx (Nasdaq: IFRX) reported it has regained compliance with Nasdaq's minimum bid price requirement under Rule 5450(a)(1). The closing bid price was at least $1.00 for 10 consecutive business days from April 13, 2026 to April 24, 2026, and Nasdaq closed the matter.
The company reiterated its lead programs, izicopan and vilobelimab, and listed investor contacts and subsidiaries.
Positive
- Regained Nasdaq compliance: closing bid ≥ $1.00 for 10 consecutive business days
- Matter closed by Nasdaq Listing Qualifications Department as of April 27, 2026
Negative
- None.
News Market Reaction – IFRX
In the Apr 28 session, IFRX gained 3.73%, reflecting a moderate positive market reaction. Argus tracked a peak move of +14.2% during that session. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Izicopan mechanistic data | Positive | +8.4% | New in vitro data supporting favorable izicopan safety and PK/PD profile. |
| Mar 31 | Conference participation | Neutral | +7.5% | Announcement of participation in Raymond James biotech symposium and pipeline overview. |
| Mar 30 | Vilobelimab Phase 3 data | Negative | -8.8% | Phase 3 PG trial stopped for futility despite some efficacy and safety signals. |
| Mar 19 | Full-year 2025 results | Neutral | +3.4% | 2025 financials, Phase 2a izicopan data, and cash runway to mid‑2027. |
| Mar 18 | AAD presentation notice | Neutral | -3.6% | Announcement of upcoming late-breaker vilobelimab Phase 3 presentation at AAD 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent IFRX news has generally seen price moves aligned with the underlying news tone, with both scientific updates and corporate events often triggering notable single-day reactions.
Over the last few months, InflaRx has reported multiple pipeline and corporate updates. On Mar 19, full-year 2025 results and funding to mid‑2027 coincided with a 3.36% move. Mechanistic izicopan data on Apr 9 and a Raymond James symposium appearance on Mar 31 saw positive reactions of 8.42% and 7.54%. By contrast, vilobelimab Phase 3 pyoderma gangrenosum data around the AAD meeting produced declines of -8.79% and -3.64%. Today’s Nasdaq compliance news fits into this pattern of discrete regulatory and clinical milestones driving sharp single‑day moves.
Key Terms
minimum bid price requirement regulatory
nasdaq listing rule 5450(a)(1) regulatory
complement system medical
c5a medical
c5ar medical
monoclonal antibody medical
phase 2a medical
phase 3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated April 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).
According to the Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Company’s ordinary shares has been
About InflaRx N.V.
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others, statements regarding our compliance with the Minimum Bid Price Rule and listing or trading of our ordinary shares. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
